252 related articles for article (PubMed ID: 32448724)
1. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
[TBL] [Abstract][Full Text] [Related]
2. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
[TBL] [Abstract][Full Text] [Related]
3. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
McKay RR; Silver R; Bhak RH; Korves C; Cheng M; Appukkuttan S; Simmons SJ; Duh MS; Taplin ME
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):210-219. PubMed ID: 32814846
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Sartor O; Appukkuttan S; Weiss J; Tsao CK
Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer.
Yang H; Kim VS; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen A; Tomlinson G; Alibhai SMH
J Geriatr Oncol; 2023 Jan; 14(1):101395. PubMed ID: 36988103
[TBL] [Abstract][Full Text] [Related]
7. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
8. Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis.
Trieu J; Chang M; Rojas V; Varada N; Cao Y; Anderson M; Vogelzang NJ
Clin Genitourin Cancer; 2022 Oct; 20(5):399-403. PubMed ID: 35680530
[TBL] [Abstract][Full Text] [Related]
9. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Sartor O; George D; Tombal B; Agarwal N; Higano CS; Sternberg CN; Miller K; Jiao X; Guo H; Sandström P; Bruno A; Verholen F; Saad F; Shore N
Future Oncol; 2022 Jan; 18(1):35-45. PubMed ID: 34636627
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.
Etchebehere EC; Milton DR; Araujo JC; Swanston NM; Macapinlac HA; Rohren EM
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):8-20. PubMed ID: 26416392
[TBL] [Abstract][Full Text] [Related]
12. Baseline quality of life predicts overall survival in patients with mCRPC treated with
Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
Rathbun JT; Franklin GE
Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
16. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Khalaf DJ; Sunderland K; Eigl BJ; Kollmannsberger CK; Ivanov N; Finch DL; Oja C; Vergidis J; Zulfiqar M; Gleave ME; Chi KN
Eur Urol; 2019 Jun; 75(6):940-947. PubMed ID: 30591354
[TBL] [Abstract][Full Text] [Related]
17. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
18. Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.
Jiménez Romero ME; Díez Farto S; Navarro Serrato JS; Canelón Castillo E; Revelo Cadena I
Exp Oncol; 2018 Jun; 40(2):144-148. PubMed ID: 29949528
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Weng WC; Huang LH; Tseng NC; Ou YC
J Formos Med Assoc; 2022 Oct; 121(10):1929-1937. PubMed ID: 35123846
[TBL] [Abstract][Full Text] [Related]
20. The safety of radium-223 combined with new-generation hormonal agents in bone metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
Wang MH; Dai JD; Zhang XM; Zhao JG; Sun GX; Zeng YH; Zeng H; Xu NW; Zeng H; Shen PF
Asian J Androl; 2023; 25(4):441-447. PubMed ID: 36695246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
